AR039211A1 - Evaluacion del cancer colorectal - Google Patents

Evaluacion del cancer colorectal

Info

Publication number
AR039211A1
AR039211A1 ARP030101132A ARP030101132A AR039211A1 AR 039211 A1 AR039211 A1 AR 039211A1 AR P030101132 A ARP030101132 A AR P030101132A AR P030101132 A ARP030101132 A AR P030101132A AR 039211 A1 AR039211 A1 AR 039211A1
Authority
AR
Argentina
Prior art keywords
colorectal cancer
cancer assessment
cancer
assessment
portfolio
Prior art date
Application number
ARP030101132A
Other languages
English (en)
Spanish (es)
Original Assignee
Ortho Clinical Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Clinical Diagnostics Inc filed Critical Ortho Clinical Diagnostics Inc
Publication of AR039211A1 publication Critical patent/AR039211A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ARP030101132A 2002-03-29 2003-04-01 Evaluacion del cancer colorectal AR039211A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36868702P 2002-03-29 2002-03-29

Publications (1)

Publication Number Publication Date
AR039211A1 true AR039211A1 (es) 2005-02-09

Family

ID=28675528

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101132A AR039211A1 (es) 2002-03-29 2003-04-01 Evaluacion del cancer colorectal

Country Status (10)

Country Link
US (1) US20030186303A1 (cg-RX-API-DMAC7.html)
EP (1) EP1355151A3 (cg-RX-API-DMAC7.html)
JP (2) JP4354725B2 (cg-RX-API-DMAC7.html)
KR (1) KR100984996B1 (cg-RX-API-DMAC7.html)
CN (2) CN101684500A (cg-RX-API-DMAC7.html)
AR (1) AR039211A1 (cg-RX-API-DMAC7.html)
AU (1) AU2003203561A1 (cg-RX-API-DMAC7.html)
BR (1) BR0303012A (cg-RX-API-DMAC7.html)
CA (1) CA2422305C (cg-RX-API-DMAC7.html)
MX (1) MXPA03002863A (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2475769C (en) * 2003-08-28 2018-12-11 Veridex, Llc Colorectal cancer prognostics
WO2005066363A2 (en) * 2004-01-09 2005-07-21 Medigen Biotechnology Corporation Cancer specific gene ccndbp1
WO2006132788A2 (en) * 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
US8249814B2 (en) * 2005-10-21 2012-08-21 Genenews Inc. Method, computer readable medium, and system for determining a probability of colorectal cancer in a test subject
WO2008045133A2 (en) * 2006-03-03 2008-04-17 Veridex, Llc Molecular assay to predict recurrence of dukes' b colon cancer
AU2008316313B2 (en) * 2007-10-23 2015-04-16 Clinical Genomics Pty. Ltd. A method of diagnosing neoplasms - II
EP2169078A1 (en) 2008-09-26 2010-03-31 Fundacion Gaiker Methods and kits for the diagnosis and the staging of colorectal cancer
WO2013092960A1 (en) 2011-12-22 2013-06-27 Fundacion Gaiker Methods and kits for the diagnosis of colorectal cancer
CN102586423B (zh) * 2011-12-27 2015-01-07 盛司潼 一种检测结直肠癌易感基因的方法及试剂盒
CN102586420B (zh) * 2011-12-27 2014-10-22 盛司潼 一种检测乳腺癌易感基因的方法及试剂盒
CN115678994B (zh) * 2022-01-27 2025-01-21 上海爱谱蒂康生物科技有限公司 一种生物标志物组合、含其的试剂及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US635152A (en) * 1899-06-05 1899-10-17 Melancthon S Shotwell Car-body bolster.
US6275814B1 (en) * 1996-11-27 2001-08-14 Investment Strategies Network Investment portfolio selection system and method
US6003018A (en) * 1998-03-27 1999-12-14 Michaud Partners Llp Portfolio optimization by means of resampled efficient frontiers
US6350578B1 (en) * 1999-06-25 2002-02-26 The Regents Of The University Of California Method of quantitating dsDNA
US6175824B1 (en) * 1999-07-14 2001-01-16 Chi Research, Inc. Method and apparatus for choosing a stock portfolio, based on patent indicators

Also Published As

Publication number Publication date
KR100984996B1 (ko) 2010-10-04
KR20030078801A (ko) 2003-10-08
JP2003325191A (ja) 2003-11-18
CN101684500A (zh) 2010-03-31
MXPA03002863A (es) 2004-08-11
US20030186303A1 (en) 2003-10-02
JP4354725B2 (ja) 2009-10-28
EP1355151A2 (en) 2003-10-22
BR0303012A (pt) 2004-09-08
CA2422305C (en) 2013-07-30
AU2003203561A1 (en) 2003-10-23
CA2422305A1 (en) 2003-09-29
JP2009153521A (ja) 2009-07-16
EP1355151A3 (en) 2004-08-25
CN1502989A (zh) 2004-06-09

Similar Documents

Publication Publication Date Title
Brunner et al. Distant metastases from cutaneous squamous cell carcinoma—analysis of AJCC stage IV
Amit et al. Incidence of cervical lymph node metastasis and its association with outcomes in patients with adenoid cystic carcinoma. An international collaborative study
ECSP17025787A (es) Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr
Ding et al. Ki-67 is an independent indicator in non–muscle invasive bladder cancer (NMIBC); Combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC
ES2634546T3 (es) Uso de células madre mesenquimales modificadas genéticamente para expresar un gen suicida para tratar un cáncer
Magnano et al. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population
MX2009006378A (es) Biomarcadores para cancer.
ATE539170T1 (de) Abschätzung und verringerung des risikos von graft-versus-host-reaktion
CO5631459A2 (es) Metodos para la deteccion de desordenes geneticos
AR039617A1 (es) Evaluacion del cancer colorectal
AR043808A1 (es) Pronostico de cancer colorrectal
MX2019000353A (es) Andamios de biomatriz para usarse en el diagnóstico y modelado del cáncer.
MX378733B (es) Métodos in vitro y composiciones para identificar y usarse en el tratamiento de lupus.
MX2020007852A (es) Metodos para el tratamiento de la atrofia muscular espinal.
DE602004015626D1 (de) Bei brustkrebs
Yeung et al. Lymph node‐positive head and neck cancer treated with definitive radiotherapy: can treatment response determine the extent of neck dissection?
WO2005083429A3 (en) Breast cancer prognostics
MX2025004103A (es) Metodos de identificacion de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
MXPA04003931A (es) Pronostico de cancer de mama.
ATE426162T1 (de) Verfahren zum untersuchen von kírperflussikeiten auf krebszellen sowie entsprechende analysekits
DE10345021A1 (de) Verfahren zur nichtinvasiven Früherkennung von Dickdarmkrebs und/oder Darmkrebsvorläuferzellen
MXPA03002863A (es) Valoracion de cancer colorrectal.
AR054357A1 (es) Metodo para evaluar la efectividad de un regimen de tratamiento
Yuasa et al. Prognostic significance of the cytogenetic evolution after the hematopoietic stem cell transplantation in adult acute myeloid leukemia

Legal Events

Date Code Title Description
FC Refusal